JP2003185655A - プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法 - Google Patents

プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法

Info

Publication number
JP2003185655A
JP2003185655A JP2002255835A JP2002255835A JP2003185655A JP 2003185655 A JP2003185655 A JP 2003185655A JP 2002255835 A JP2002255835 A JP 2002255835A JP 2002255835 A JP2002255835 A JP 2002255835A JP 2003185655 A JP2003185655 A JP 2003185655A
Authority
JP
Japan
Prior art keywords
fluorescent marker
proline
domain
peptide
rich
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002255835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003185655A5 (enExample
Inventor
Mendez Isabelle De
デ メンデ イザベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2003185655A publication Critical patent/JP2003185655A/ja
Publication of JP2003185655A5 publication Critical patent/JP2003185655A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2002255835A 2001-07-30 2002-07-29 プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法 Abandoned JP2003185655A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402064A EP1281962A1 (en) 2001-07-30 2001-07-30 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and an SH3 domain comprising peptide
EP01402064.8 2001-07-30

Publications (2)

Publication Number Publication Date
JP2003185655A true JP2003185655A (ja) 2003-07-03
JP2003185655A5 JP2003185655A5 (enExample) 2005-10-27

Family

ID=8182834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002255835A Abandoned JP2003185655A (ja) 2001-07-30 2002-07-29 プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法

Country Status (3)

Country Link
EP (1) EP1281962A1 (enExample)
JP (1) JP2003185655A (enExample)
CA (1) CA2395992A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069604A1 (ja) * 2005-12-14 2007-06-21 National University Corporation Hokkaido University 修飾蛋白質の製造方法
JPWO2023032994A1 (enExample) * 2021-08-31 2023-03-09

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2285047B (en) * 1993-12-21 1998-04-15 Yamanouchi U K Ltd Polypeptides which inhibit the NADPH oxidase complex
US5955259A (en) * 1996-12-19 1999-09-21 Brandeis University Method for assessing modulation of potassium ion channel activity
CA2300869A1 (en) * 1997-09-04 1999-03-11 Ron Vale Assays for detecting modulators of cytoskeletal function
CA2377560C (en) * 1999-06-24 2010-08-24 Mcmaster University Incorporation and applications of biomolecular interactions within a carrier
WO2001042453A1 (fr) * 1999-12-06 2001-06-14 Biomolecular Engineering Research Institute Coordonnees structurales et decalage chimique rmn de proteine; utilisation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069604A1 (ja) * 2005-12-14 2007-06-21 National University Corporation Hokkaido University 修飾蛋白質の製造方法
JPWO2023032994A1 (enExample) * 2021-08-31 2023-03-09
WO2023032994A1 (ja) * 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質

Also Published As

Publication number Publication date
CA2395992A1 (en) 2003-01-30
EP1281962A1 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
US6207397B1 (en) In vitro fluorescence polarization assay
EP0750630A1 (en) Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
Llorian et al. SIPP1, a novel pre-mRNA splicing factor and interactor of protein phosphatase-1
Hock et al. Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions
AU727108B2 (en) In vitro fluorescence polarization assay
JP2006519800A (ja) 未分化リンパ腫キナーゼアッセイ、試薬及びその組成物
JP2007525988A (ja) Ｏ６−アルキルグアニン−ｄｎａアルキルトランスフェラーゼの突然変異体
US6011137A (en) Identification and isolation of novel polypeptides having WW domains and methods of using same
JP2003501095A (ja) ディクチオステリウムからのｃＡＰＭ依存プロテインキナーゼ（ＰＫＡ）の制御サブユニットのｃＡＰＭ測定のための使用
US6187552B1 (en) Method for identifying inhibitors of JAK2/cytokine receptor binding
Yoon et al. Differences between AGAP1, ASAP1 and Arf GAP1 in substrate recognition: interaction with the N-terminus of Arf1
US5888763A (en) Peptides specific for the first Crk-SH3 domain
Xu et al. Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase
JP2006515159A (ja) Ｍｋ２相互作用タンパク質
WO1996021011A9 (en) PEPTIDES SPECIFIC FOR THE FIRST Crk-SH3 DOMAIN
WO2005019472A1 (ja) シノビオリン活性調節作用の検出方法
JP2009514529A (ja) Ｔｒｐｍ８およびカルモジュリンのポリペプチド複合体ならびにそれらのその用途
US20030108975A1 (en) Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a SH3 domain comprising peptide
WO2003068808A1 (en) Novel protein complexes and uses therefor
US7790843B2 (en) Cypin polypeptide and fragments thereof
EP1281962A1 (en) Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and an SH3 domain comprising peptide
US20060088901A1 (en) Methods and kits for determining ubiquitin protein ligase (E3) activity
JPWO2005118841A1 (ja) シノビオリンのユビキチン化のアッセイ及びスクリーニングへの利用
WO2007089899A2 (en) Water-soluble (g protein)-coupled receptor protein
CA2219958A1 (en) The g-protein .beta.subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050721

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20060526

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060526